FRI-329-Comparison of seladelpar and combinations with liraglutide or selonsertib for improvement of fibrosis and NASH in a diet-induced and biopsy-confirmed mouse model of NASH

New Drugs for Hepatic Fibrosis

“…The results of animal experiments showed that Liraglutide could significantly reduce collagen fibers in NAFLD models ( Fagone et al, 2016 ; Choi et al, 2019 ; Briand et al, 2020 ). Moreover, Liraglutide significantly reduced levels of inflammatory factors, such as IL-6 and TNF-α, and liver fibrosis factors in the NAFLD model group ( Fagone et al, 2016 ; Choi et al, 2019 ; Briand et al, 2020 ).…”

“…The results of animal experiments showed that Liraglutide could significantly reduce collagen fibers in NAFLD models ( Fagone et al, 2016 ; Choi et al, 2019 ; Briand et al, 2020 ). Moreover, Liraglutide significantly reduced levels of inflammatory factors, such as IL-6 and TNF-α, and liver fibrosis factors in the NAFLD model group ( Fagone et al, 2016 ; Choi et al, 2019 ; Briand et al, 2020 ). Liraglutide may play an important role in NAFLD by activating the SIRT1/AMPK pathway, regulating key regulatory molecules of lipid synthesis and metabolism, and inhibiting the de novo synthesis of fatty acids ( Kahal et al, 2014 ).…”

“…Liraglutide may play anti-inflammatory and anti-fibrosis roles by inhibiting the activation of NF-κB and reducing the production of superoxide ( Fagone et al, 2016 ). Liraglutide can also reduce the degree of tissue collagen deposition and improve tissue fibrosis ( Armstrong and Newsome, 2015 ; Choi et al, 2019 ; Briand et al, 2020 ), and may play an anti-fibrosis role by regulating some important links in the fibrotic process ( Armstrong et al, 2015 ; Armstrong et al, 2016 ; Gaborit et al, 2016 ; Choi et al, 2019 ). The data from genetic toxicity studies show that Liraglutide is not toxic in the human body ( Armstrong et al, 2015 ; Armstrong et al, 2016 ; Gaborit et al, 2016 ).…”